[DreaMed in PR Newswire] DreaMed Diabetes Granted FDA Authorization to Market Advisor Pro, Offering Personalized Optimization of Insulin Pump Therapy

DreaMed Diabetes, developer of personalized diabetes management solutions, announced today that the U.S Food and Drug Administration (FDA) has granted a De Novo request for DreaMed Advisor Pro, an artificial intelligence (AI)-based diabetes treatment decision support software.

Read more on PR Newswire here.